🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
The purpose of this study is to compare two measles, mumps and rubella conj...
Status
Completed
Location
GSK Investigational Site
Start Date
2009-06-03
Trial ID
NCT00861744
The research was conducted as a randomized controlled experiment to investi...
Status
Completed
Location
Istanbul Okan University
Start Date
2018-11-15
Trial ID
NCT04990648
Treatments Being Tested
Follow-up to evaluate the immunogenicity and safety of three production lot...
Status
Completed
Location
GSK Investigational Site
Start Date
2004-07
Trial ID
NCT00406211
Treatments Being Tested
The primary objectives of this study are to evaluate the immunogenicity and...
Status
Completed
Location
Multiple Locations
Start Date
2012-03-30
Trial ID
NCT01553279
Treatments Being Tested
The primary objective of this study is to demonstrate the non-inferiority o...
Status
Completed
Location
Alabama Clinical Therapeutics Site Number : 8400036
Start Date
2018-10-04
Trial ID
NCT03691610
Treatments Being Tested
The purpose of this study is to investigate the potential for co-administra...
Status
Completed
Location
Multiple Locations
Start Date
2010-01
Trial ID
NCT01064141
Treatments Being Tested
RATIONALE: Antithymocyte globulin, clofarabine, and rituximab may stop the ...
Status
Terminated
Location
Masonic Cancer Center at University of Minnesota
Start Date
2008-01
Trial ID
NCT00617929
Treatments Being Tested
The study was designed to test the following hypotheses: In patients with ...
Status
Unknown
Location
Hopital Universitaire
Start Date
2013-01
Trial ID
NCT01820598
Treatments Being Tested
Primary objective: This study aimed to demonstrate the non-inferiority of ...
Status
Completed
Location
Investigational Site Number : 2031006
Start Date
2018-12-14
Trial ID
NCT03547271
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growt...
Status
Completed
Location
Alaska Regional Hospital Cancer Center
Start Date
2006-08
Trial ID
NCT00376961
Treatments Being Tested